Abstract
Cytomegalovirus (CMV) continues to be a substantial problem for transplant patients. Although several agents are available with activity against CMV, the primary drug used over the past 15 years is ganciclovir. Because of poor absorption of oral ganciclovir, which results in the need for frequent and large oral doses, the valine ester of ganciclovir, valganciclovir, was developed. Valganciclovir provides 10-fold higher bioavailability allowing smaller doses given once a day. With the high ganciclovir blood levels achieved, the ability to treat CMV with an oral medication is being explored. This review provides an update on valganciclovir, highlighting areas of ongoing study including appropriate drug dose, length of prophylaxis, pediatric use, and use for preemptive treatment and treatment of established disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
